IBNtxA is 10-fold more potent than morphine in thermal assays and even more effective in inflammatory and neuropathic pain models. 3 Unlike traditional opioids, IBNtxA does not produce respiratory depression, physical dependence, or reward behavior in a conditioned place preference assay and shows no cross tolerance to morphine. [1] [2] [3] Although IBNtxA analgesia is mediated through the μ-opioid receptor gene OPRM1, it acts through a target that is genetically distinct from morphine.
The single-copy μ-opioid receptor gene (OPRM1) undergoes extensive alternative precursor messenger ribonucleic acid (pre-mRNA) splicing, generating multiple splice BACKGROUND: Most clinical opioids act through μ-opioid receptors. They effectively relieve pain but are limited by side effects, such as constipation, respiratory depression, dependence, and addiction. Many efforts have been made toward developing potent analgesics that lack side effects. Three-iodobenzoyl-6β-naltrexamide (IBNtxA) is a novel class of opioid active against thermal, inflammatory, and neuropathic pain, without respiratory depression, physical dependence, and reward behavior. The μ-opioid receptor (OPRM1) gene undergoes extensive alternative precursor messenger ribonucleic acid splicing, generating multiple splice variants that are conserved from rodents to humans. One type of variant is the exon 11 (E11)-associated truncated variant containing 6 transmembrane domains (6TM variant). There are 5 6TM variants in the mouse OPRM1 gene, including mMOR-1G, mMOR-1M, mMOR-1N, mMOR-1K, and mMOR-1L. Gene-targeting mouse models selectively removing 6TM variants in E11 knockout (KO) mice eliminated IBNtxA analgesia without affecting morphine analgesia. Conversely, morphine analgesia is lost in an exon 1 (E1) KO mouse that lacks all 7 transmembrane (7TM) variants but retains 6TM variant expression, while IBNtxA analgesia remains intact. Elimination of both E1 and E11 in an E1/E11 double KO mice abolishes both morphine and IBNtxA analgesia. Reconstituting expression of the 6TM variant mMOR-1G in E1/E11 KO mice through lentiviral expression rescued IBNtxA but not morphine analgesia. The aim of this study was to investigate the effect of lentiviral expression of the other 6TM variants in E1/E11 KO mice on IBNtxA analgesia. METHODS: Lentiviruses expressing 6TM variants were packaged in HEK293T cells, concentrated by ultracentrifugation, and intrathecally administered 3 times. Opioid analgesia was determined using a radiant-heat tail-flick assay. Expression of lentiviral 6TM variant messenger ribonucleic acids was examined by polymerase chain reaction (PCR) or quantitative PCR. RESULTS: All the 6TM variants restored IBNtxA analgesia in the E1/E11 KO mouse, while morphine remained inactive. Expression of lentiviral 6TM variants was confirmed by PCR or quantitative PCR. IBNtxA median effective dose values determined from cumulative dose-response studies in the rescued mice were indistinguishable from wild-type animals. IBNtxA analgesia was maintained for up to 33 weeks in the rescue mice and was readily antagonized by the opioid antagonist levallorphan. CONCLUSIONS: Our study demonstrated the pharmacological relevance of mouse 6TM variants in IBNtxA analgesia and established that a common functional core of the receptors corresponding to the transmembrane domains encoded by exons 2 and 3 is sufficient for activity. Thus, 6TM variants offer potential therapeutic targets for a distinct class of analgesics that are effective against broad-spectrum pain models without many side effects associated with traditional opioids. (Anesth Analg 2018;126:1050-7)
Truncated μ-Opioid Receptors With 6 Transmembrane Domains Are Essential for Opioid Analgesia variants with a pattern that is conserved from rodents to humans. 4 These splice variants fall into 3 structurally distinct categories ( Figure 1 ). The exon 1 (E1)-associated full-length 7 transmembrane (7TM) proteins are most abundant. They are identical except for the sequences at the tip of the intracellular C-terminus. The second set, the E1-associated truncated 1 transmembrane (1TM) variants, possess only the N-terminus and first TM present in the full-length 7TM receptors with alternative C-termini. The third class is the E11-associated truncated 6TM variants. These lack the first TM present in the full-length 7TM receptors. The functional relevance of the 7TM splice variants was based on their unique region-and/ or cell-specific expression, µ agonist-induced G protein coupling, phosphorylation, internalization and postendocytic sorting, and their involvement in vivo morphine activity. 1, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] The truncated 1TM variants do not bind ligand, but function as molecular chaperones that facilitate expression of the 7TM µ receptor and thereby enhance morphine analgesia.
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OPRM1 gene-targeting mouse models provide useful tools to decipher the function of truncated 6TM splice variants (Table) . IBNtxA analgesia was completely abolished in E11 knockout (KO) mice lacking all the truncated 6TM variants while still expressing the 7TM C-terminal variants, despite the fact that morphine analgesia remained intact. 1, 4, 20 Conversely, the selective loss of all the 7TM variants in an E1 KO mouse that still expressed the 6TM variants 19 eliminated morphine analgesia, but not IBNtxA analgesia. 1, 4 This residual analgesia did not involve δ or κ receptors since IBNtxA showed full analgesic activity in a triple KO mouse lacking δ, κ, and E1-associated 7TM and 1TM receptors. 1 Together, these studies suggest that E11-associated 6TM variants mediate IBNtxA analgesia while E1-associated 7TM variants are responsible for morphine analgesia. A gain-of-function study further established the role of a 6TM variant, mMOR-1G, in IBNtxA analgesia. 16, 21 In a complete μ-opioid receptor (OPRM1) KO mouse in which both exons 1 and 11 (E1/E11 KO) were targeted, eliminating expressions of all OPRM1 variants, both morphine and IBNtxA were inactive. Expressing mMOR-1G through lentiviralmediated delivery in the E1/E11 KO mice rescued IBNtxA, but not morphine, analgesia, suggesting that mMOR-1G is both necessary and sufficient for IBNtxA analgesia.
Mice express 5 E11-associated 6TM variants: mMOR-1G, mMOR-1M, mMOR-1N, mMOR-1K, and mMOR-1L, with mMOR-1K and mMOR-1L producing identical proteins. Their structures encompassing the transmembrane C-terminal full-length 7TM variants, truncated 1TM variants, and 6TM variants. These variants are conserved from rodent to humans (see review 4 for complete list, including exon composition and sequences). The N-terminus and intracellular and extracellular loops are indicated by color-coded lines, and transmembrane domains are shown by color-coded cylinders. Each color presents the coding region predicted from an exon. Note: Because the translation start point of mMOR-1K and mMOR-1L is in exon 2, these variants will not contain the amino acid sequences associated with exon 11 (blue line). Pre-mRNA indicates precursor messenger ribonucleic acid; 1TM, 1 transmembrane; 6TM, 6 transmembrane; 7TM, 7 transmembrane.
www.anesthesia-analgesia.org ANESTHESIA & ANALGESIA Truncated 6TM μ-Opioid Receptors and Analgesia domains and loops that are encoded by exons 2 and 3 are identical, but their C-terminal sequences vary, and mMOR-1K and mMOR-1L lack the N-terminal amino acid sequence encoded by E11. The present study examines whether the rescue of IBNtxA analgesia was selective for mMOR-1G or could be extended to the other 6TM variants. Understanding the structural requirements for 6TM activity would be helpful in the development of novel, safer analgesic drugs.
METHODS Animals
The E1/E11 KO mouse in a mixture of 129S6/SvEvTac (Taconic)/C57BL/6J (Jackson Laboratory, Bar Harbor, ME) background was generated as described previously. 16 Adult (8-16 weeks old) wild-type (WT) and homozygous (KO) male mice were used. All mice were housed in groups of 5, maintained on a 12-hour light/dark cycle and given ad libitum access to food and water. All animal studies were approved by the Institutional Animal Care and Use Committee of the Memorial Sloan-Kettering Cancer Center. All animal studies were performed in our standard behavioral procedure room between 9:00 am and 5:00 pm.
Drugs
Morphine sulfate was obtained from the Research Technology Branch of the National Institute on Drug Abuse (Rockville, MD). Levallorphan (L121) was purchased from Sigma-Aldrich (St. Louis, MO), and IBNtxA was synthesized and the structure validated. 22 
Lentiviral Vector Construction, Production, and Injection
Lentiviral constructs, production, and injection were performed as described previously. 16 Lentiviral vectors are obtained as gifts from Dr Didler Trono, Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland. We first subcloned a 78 bp polylinker containing XhoI/SpeI/AscI/MluI/NdeI/BamHI/ XmaI/XbaI sites into the PmeI site in pWPI to facilitate cloning. A ~500 bp polymerase chain reaction (PCR) fragment containing the internal ribosome entry site of the Food and Mouth Disease Virus was then inserted into AscI/MluI sites as pWPI-IRES to enhance the translation of inserted complementary deoxynucleic acid. mMOR-1M, mMOR-1N, and mMOR-1K or mMOR-1L (exons 2/3/4) amplified by PCR using a sense primer (SP) flanked with MluI and an anti-SP (AP) flanked with XmaI were subcloned into MluI/XmaI sites of pWPI-IRES. pWPI-IRES-mMOR-1G was constructed as described previously. 16 The viral particles were generated in HEK293T cells by cotransfecting pWPI-IRES constructs with a packaging vector, PAX2, and an envelope vector, PMD2G, by using FuGENE HD transfection reagent (Promega, Madison, WI ). After 24-hour transfection, the supernatants were collected, filtered, and concentrated by ultracentrifugation (100,000g, 2 hours) in Beckman L7-55 ultracentrifuge (Beckman Coulter, Brea, CA). The viral titer of the concentrated lentiviral particles was determined by quantifying enhanced green fluorescent protein (EGFP) -expressing cells in transduced HEK293T cells with various dilutions using Tali Image-Based Cytometer (Invitrogen, Carlsbad, CA). Intrathecal (i.t.) injections were performed by lumbar puncture using a Hamilton 10 µL syringe fitted to a 30-gauge needle with PE-20 polyethylene tubing (Becton-Dickinson, Franklin Lakes, NJ) under general isoflurane anesthesia (1%-4%). Two microliters of the lentiviral particles expressing a 6TM variant or vector alone (~1.5 × 10 9 transducing units/mL) were i.t. administered 3 times on days 1, 3, and 5.
Opioid Analgesia
Analgesia was determined using the radiant-heat tail-flick assay, with a maximal latency of 10 seconds to minimize tissue damage, as described previously. 16, 20 Results were calculated as the percentage of maximum possible effect ([latency after drug -baseline latency]/[10 -baseline latency] × 100). Morphine or IBNtxA was administered subcutaneously (s.c.) at the indicated doses. Analgesia was assessed 30 minutes after injection at peak effect. Cumulative dose-response studies utilized escalating IBNtxA doses (0.1, 0.3, 1, 3, and 10 mg/kg), with the next higher dose administered immediately after analgesia testing of the previous dose. Median effective dose (ED 50 ) values with 95% confidence intervals were determined using nonlinear regression analysis using a 2-parameter logistic model, a special case of the 4-parameter logistic model with fixed lower and upper asymptotes at 0% and 100%, respectively (GraphPad Prism, San Diego, CA). To examine levallorphan antagonism, the drug (2.5 mg/kg, s.c.) was given 15 minutes before IBNtxA (2.5 mg/kg, s.c.) and analgesia assessed 30 minutes after IBNtxA.
Reverse Transcription and PCR and SYBR Green Quantitative PCR
Ribonucleic acid (RNA) isolation, reverse transcription and PCR, and quantitative PCR (qPCR) were performed as described previously. 16, 23 Mice were euthanized by rapid cervical dislocation, and the lumbar and thoracic sections of the spinal cord were dissected for total RNA isolation. Total RNAs were isolated using RNeasy Kit (Qiagen, Valencia, CA) following manufacturer protocol, treated with DNase I using Turbo DNA-free reagents (Invitrogen), and reverse transcribed with Superscript III (Invitrogen) and random primers. The first-strand complementary deoxynucleic acids were used in PCR to amplify a 402 bp fragment of exons 1-2 ([an SP: 5′-GGC TCC TGG CTC AAC TTG TCC CAC-3′ and an AP: 5′-GGT GCA GAG GGT GAA GAT ACT GGT GAA C-3′]) for all 7TM variants, a 551 bp fragment of exons 2-3 (SP: 5′-GTA TCT TCA CCC TCT GCA CCA TGA GTG-3′ and AP: 5′-CGC ATA AAG AAC TGG GTT CAG GCA GC-3′) for both 7TM and 6TM variants, a 242 bp fragment of EGFP (SP: 5′-GGA CGG CAA CAT CCT GGG GC-3′ and AP: 5′-CGT TGG GGT CTT TGC TCA GGG C-3′) for lentivirus, and a 432 bp fragment of glyceraldehydes 3-phosphate dehydrogenase (G3PDH) (SP: 5′-ACC ACA GTC CAT GCC ATC AC-3′ and 5′-TCC ACC ACC CTG TTG CTG TA-3′) for RNA loading control. All PCR reactions were performed in DNA Engine PTC-200 (Bio-Rad, Hercules, CA) using Platinum Taq deoxyribonucleic acid (DNA) polymerase (Invitrogen) for 35 cycles after 2 minutes at 94°C, each cycle consisting of a 20-second denaturing step at 94°C, a 20-second annealing step at 65°C (60°C for G3PDH), and 1-minute extension at 72°C. PCR products were separated on 2% agarose gel, stained with ethidium bromide, and imaged using a ChemiDoc MP system (Bio-Rad). SYBR green qPCRs were performed in the CFX96 machine (Bio-Rad) to amplify exons 2-3 (E2-3) using the above primers and HotStart Taq SYBR Green Master Mix (Affymetrix, Santa Clara, CA). After 2 minutes at 95°C, it ran 50 cycles, each cycle containing a 15-second denaturing step at 95°C, a 30-second annealing step at 65°C (60°C for G3PDH), and a 1-minute extension at 72°C. Melting curve analysis was conducted subsequently. qPCR for G3PDH was used for normalization using 2 −∆C(t) (delta cycle threshold) (ΔC(t) = C(t) E2-3 -C(t) G3PDH ). Expression level (%) was calculated by normalizing with the mean of WT (expression level = 2 −∆C(t) sample/2 −∆C(t) WT [the mean] × 100). So the WT level is 100%.
Statistics
All mice were randomized and assigned to groups. Some, but not all, experiments were performed under blinded conditions. Data from qPCR, levallorphan, and morphine analgesia studies were analyzed using 1-way analysis of variance with post hoc Bonferroni multiple comparison test (GraphPad Prism). The time course of IBNtxA analgesia was analyzed using repeated-measures analysis of variance. Data represented the means ± standard error of the mean of 3 or more independent samples. Statistical significance was set at P < .05.
RESULTS
To examine the role of the individual 6TM variants in IBNtxA analgesia, we first made lentiviruses expressing mMOR-1M, mMOR-1N, or mMOR-1K/L (ie, exons 2/3/4) along with EGFP proteins for comparison with the earlier mMOR-1G lentivirus. The EGFP marker located downstream of the receptor cassette in each vector was cotranslated through an encephalomyocarditis virus IRES, providing a marker of lentivirus expression. We then expressed these lentiviruses in the E1/E11 KO mice that lost both IBNtxA and morphine analgesia (Table) to see if these 6TM variants can rescue IBNtxA analgesia. The mMOR-1M, mMOR-1N, and mMOR-1K/L lentiviruses were administered spinally (i.t.) to the E1/E11 KO mice on days 1, 3, and 5 as previously described. 16, 21 Lentivirus administered with paradigm achieved maximal expression after approximately 3-5 weeks and maintained similar expression levels for at least a year (unpublished observation). We included a mMOR-1G lentivirus group to provide a comparison with the new 6TM variants and to confirm our prior study. The EGFP mRNA was detected in all lentiviral-transduced animals, including lentiviral vector alone, confirming viral expression, but it was not found in the WT or KO controls (Figure 2A) . We examined mRNA expression of the specific 6TM variants with PCR using a pair of exon 2 and exon 3 (E2-3) primers to amply exons 2 and 3 mRNA since these primers will detect all the 6TM variants. All lentiviral 6TM transduced animals expressed the exons 2 and 3 mRNA, confirming expression of the individual 6TM variants in these animals (Figure 2A) . The expression level of the lentiviral 6TM variant mRNA was similar to that of WT controls ( Figure 2B ). Untreated and vector-alone-treated E1/E11 KO mice failed to reveal The same samples (n = 4-6 per group) as described above were used in SYBR green qPCRs with the E2-3 primers in 1 experiment. Normalized expression was calculated as: 2 −∆C(t) using G3PDH (ΔC(t) = C(t) variant -C(t) G3PDH ). Expression levels (%) were calculated by normalizing with the mean of WT (expression level = 2 −∆C(t) sample/2 −∆C(t) WT [the mean] × 100) so the WT level is 100%. Compared to E1/E11 KO or vector, #: P < .001; @: P < .0001 (1-way ANOVA with Bonferroni post hoc test). There was no significant difference between WT and any of the 6TM variants. ANOVA indicates analysis of variance; E1/E11 KO, exons 1 and 11 knockout; EGFP , enhanced green fluorescent protein; G3PDH, glyceraldehydes 3-phosphate dehydrogenase; mRNAs, messenger ribonucleic acid; qPCR, Quantitative polymerase chain reaction; RNA, ribonucleic acid; RT-PCR, reverse transcription and polymerase chain reaction; 6TM, 6 transmembrane; WT, wild type.
www.anesthesia-analgesia.org ANESTHESIA & ANALGESIA Truncated 6TM μ-Opioid Receptors and Analgesia any PCR product, verifying the specificity of 6TM variant expression. No E1-associated 7TM variant transcripts using E1 and exon 2 (E1-2) primers were observed, confirming the lack of any full-length 7TM μ-opioid receptors in either KO or in any lenvirus transduced animals (Figure 2A ), proving lack of any 7TM variants in E1/E11 KO mice.
IBNtxA analgesia was assessed using a radiant-heat tail-flick assay. Untreated E1/E11 KO mice displayed no appreciable IBNtxA analgesia ( Figure 3A, time 0) , consistent with the absence of E11-associated 6TM variants (Table) . 16 However, IBNtxA analgesia was fully restored in all 6TM lentivirus groups, starting 3 weeks after injection, with maximal responses remaining unchanged for the duration of the studies ( Figure 3A) . 16 The results from lentiviral mMOR-1G group were consistent with those from the previous study, 16 providing a confirmatory replication. The effects of IBNtxA analgesia rescue in other 3 lentiviral 6TM groups were similar to that in lentiviral mMOR-1G group, suggesting that all individual 6TM variants can restore IBNtxA analgesia. The vector alone failed to rescue IBNtxA analgesia ( Figure 3A) despite expression of the lentivirus alone, as indicated by expression of the EGFP marker (Figure 2A) . The 6TM did not affect morphine analgesia. Morphine remained totally inactive in all lentivirus-treated and in the E1/E11 KO mice ( Figure 3C) .
We then evaluated the rescued IBNtxA analgesia potency using cumulative dose-response curve study. Cumulative dose-response curve of lenti-mMOR-1G group revealed an ED 50 value (0.73 mg/kg) (Figure 4) , which is similar to Figure 3 . Rescue of IBNtxA analgesia in E1/E11 KO mice. A, Time course of IBNtxA analgesia. Lentiviruses expressing mMOR-1G, mMOR-1M, and mMOR-1N (n = 8) or mMOR-1K/L (n = 16) or vector (n = 6) were i.t. administered into E1/E11 KO mice, as described in Methods. WT mice (n = 6) were used as control at 0 wk. IBNtxA analgesia (2.5 mg/kg, s.c. a dose >4-fold ED 50 in WT mice) was examined in indicated time before (0 wk) or after the lentiviral injection in 1 experiment. Repeated measures ANOVA analysis showed a statistically significant effect of time (F(3,123) = 118.7, P < .0001), group (F(4,41) = 13.34, P < .0001), and interaction of time × group (F(12,123) = 5.38, P < .0001). For effect of time within a group, all 4 6TM groups had a significant effect with P < .0001 except for vector group, P = .4316. For pairwise comparison across time within a group, *: P < .05; #: P < .001; @: P < .0001. B, Effect of levallorphan on IBNtxA analgesia. IBNtxA analgesia without levallorphan was assessed at 5 wk after lentiviral injection (data including WT mice adapted from Figure 3A ). E1/E11 KO mice (n = 6) were included as a control. Levallorphan study was performed at 34 wk (mMOR-1, mMOR-1M, and mMOR-1N that (1.1 mg/kg) from the previous study, 16 again providing a confirming replication. The other 6TM lentivirus groups, including mMOR-1M, mMOR-1N, and mMOR-1K/L, had similar ED 50 values (0.4-0.8 mg/kg) that were indistinguishable from the WT control group (0.57 mg/kg; Figure 4) . Thus, the rescued mice regained full sensitivity toward IBNtxA. Vector-treated E1/E11 KO mice displayed a small increased latency at high IBNtxA doses, similar to that previously observed, 16 raising the possibility that very high IBNtxA doses may lose their selectivity for 6TM mechanisms.
The sensitivity of IBNtxA analgesia to the opioid antagonist levallorphan confirmed the opioid nature of the response. We chose levallorphan based on its higher affinity for the E11 binding site in brain than naloxone. 1 All the rescued IBNtxA analgesia was blocked by levallorphan ( Figure 3B ). Thus, 6TM variants are both necessary and sufficient for IBNtxA analgesia and are not involved with morphine actions.
DISCUSSION
When first identified, the truncated 6TM variants presented an enigma. With a structure unlike traditional G protein couple receptors (GPCRs), the functional relevance of these proteins was unclear. KO models provided the first suggestion that these variants were relevant. 1, 20 Elimination of the 6TM variants in an E11 KO mouse had no appreciable effect on morphine or methadone analgesia, but eliminated IBNtxA analgesia (Table) , illustrating the marked differences in receptor mechanisms between the 2 drugs. This was confirmed by the retention of IBNtxA analgesia in the E1 KO mouse that did not respond to morphine. However, the strongest evidence for the importance of 6TM variants in IBNtxA actions was provided by rescue studies. 16 Using the E1/E11 KO mouse, which does not express any OPRM1 gene products, i.t. administration of a lentivirus expressing the 6TM mMOR-1G rescued IBNtxA, but not morphine, analgesia. mMOR-1G is one of 5 different 6TM variants ( Figure 1B) , leaving open the question of whether the rescue was selective for mMOR-1G or would extend to all the 6TM variants.
Using a similar gain-of-function approach, the present study establishes the ability of 4 additional mouse 6TM variants to rescue IBNtxA analgesia. Each variant rescued the response, illustrating the utility of lentiviral-mediated gene delivery in studying individual OPRM1 splice variants in vivo. Structurally, all 5 E11-associated 6TM variants share a common core sequence encoded by exons 2 and 3 that comprises the 6TM domains, 2 intracellular loops, 3 extracellular loops, and a portion of the intracellular C-terminal sequences (Figure 1 ). They all are generated through the E11 promoter and their transcripts include E11, but alternative splicing yields differing N-terminal and C-terminal sequences. While mMOR-1G, mMOR-1M, and mMOR-1N translate E11, mMOR-1K and mMOR-1L do not due to insertion of exon 13 or exon 14 between exons 11 and 2 that lead to early termination of translation in exon 13 (mMOR-1K) or 14 (mMOR-1L) when using the E11 AUG (translational start codon). Initiating translation with the AUG at the beginning of exon 2 yields a 6TM receptor without the N-terminal 27 amino acid sequences (MMEAFSKSAFQKLRQRDGNQEGKSYLR) encoded by E11. Therefore, mMOR-1K and mMOR-1L encode identical 6TM proteins.
The 6TM variants also undergo 3′ splicing with a range of alternative exons downstream of exon 3 ( Figure 1B) . While mMOR-1G, mMOR-1K, and mMOR-1L all contain exon 4, which encodes 12 amino acids (LENLEAETAPLP), the other 2 replace those 12 amino acids by either the 52 amino acids (PTLAVSVAQIFTGYPSPTHVEKPCK SCMDRGMRNLLPDDGPRQESGEGQLGR) encoded by exons 7/8/9 in mMOR-1M or with 7 amino acids (RNEEPSS) encoded by exon 8 in mMOR-1N.
Despite these different C-terminal or N-terminal sequences, all the variants rescued IBNtxA analgesia, suggesting that the C-terminal differences and the E11 coding sequence have limited influence on their ability to restore IBNtxA analgesia. Although each of the variants is capable of rescuing the response, we still do not know whether a specific 6TM is responsible for IBNtxA activity in WT mice. Lentivirus transduction leads to a wide distribution of 6TM expression throughout the spinal cord when given i.t. and throughout the brainstem and much of the brain when injected intracerebroventricularly. 16, 21 While any of the 6TM variants may restore the response, they may not be acting in cells that normally express them. Regional mRNA studies showed marked differences in variant expression while immunohistochemical studies revealed cell-specific expression of C-terminal epitopes. 6, 7 Thus, the specific variant(s) responsible for activity in WT mice remain unclear.
Our study confirms that 6TM variants are the only OPRM1 variants involved with IBNtxA analgesia, being both necessary and sufficient. Other opioid receptor classes also are not involved since IBNtxA analgesia remained intact in a "triple KO" mouse lacking the full-length E1-associated 7TM µ receptor variants as well as κ and δ opioid receptors. 1 The inability of the 6TM variants to rescue morphine analgesia confirmed previous study reports 16, 19, 20 demonstrating the dependence of morphine on only 7TM variants and provides additional evidence dissociating the receptor mechanisms of morphine and IBNtxA. Thus, 6TM variants represent novel targets for a distinct class of analgesics that have a superior pharmacological profile in view of their broad analgesic activity in thermal, inflammatory, and neuropathic pain models 3 coupled with the absence of respiratory depression, physical dependence, and reward behavior. 1 Humans also express truncated 6TM OPRM1 variants. 4 Four 6TM variants, hMOR-1G1, hMOR-1G2, hMOR-1K, and μ 3 , have been identified in the human OPRM1 gene. [24] [25] [26] hMOR-1G2 is a homolog of mouse mMOR-1G, while hMOR-1G1, hMOR-1K, and μ 3 utilize the exon 2 AUG to generate identical proteins analogous to mMOR-1K and mMOR-1L. Although the in vivo activity of these human 6TM variants remains unknown, the similarities to mouse splicing suggest that they play a similar role in humans as in mice. This is supported by the clinical observations that opioids shown to be dependent on E11 mechanisms in mice, such as buprenorphine, 27 are potent analgesics in humans. The human splice variants also share other properties observed in mice. Prior studies revealed marked regional variations in expression for a range of mouse OPRM1-generated mRNAs. 23 Similarly, the expression of human 6TM variant mRNAs varies among brain regions. 24 For example, hMOR-1G2 was highly expressed in the prefrontal cortex, piriform cortex, nucleus accumbens, pons, and cerebellum, while it was less abundant in the spinal cord and temporal cortex. 24 hMOR-1G1 was only detected in the pons and cerebellum. Similarly, hMOR-1K expression was variable among the frontal lobe, nucleus accumbens, pons, and spinal cord. 25 Several single nucleotide polymorphisms (SNPs) in the human OPRM1 gene regulate μ-opioid receptor splice variant expression. An intronic SNP (rs9479757) associated with the severity of heroin addiction among Han-Chinese male heroin addicts modulates heterogeneous ribonucleoprotein H (a splicing factor) binding to promote exon 2 skipping, leading to altered expressions of 1TM variant mRNAs and MOR-1 proteins. 28 An A118G SNP (rs1799971) associated with heroin addiction and opioid responses altered expressions of MOR-1 mRNA and its protein. [29] [30] [31] An SNP (rs563649) located in the 5′ untranslated region of a human 6TM variant, hMOR-1K, affects hMOR-1K expression at both the transcriptional and translational levels, and it is associated with individual variations in pain perception. 25 These studies highlight genetic influences on gene expression involving OPRM1 alternative splicing that may contribute to the variable opioid responses in people.
Several technologies, such as RNA interference, antisense oligonucleotide, and clustered regularly interspaced short palindromic repeats/Cas9 endonuclease, can be used to treat human diseases through modulation of gene expression. For example, an antisense oligonucleotide-based drug (SPINRAZA [nusinersen], Biogen, Cambridge, MA) that corrects expression of survival of motor neuron 2 gene has recently approved by US Food and Drug Administration to treat spinal muscular atrophy as the first-ever approved therapy for this disease. We recently used a vivo-morpholino oligonucleotide to selectively reduce expression of a set of μ-opioid receptor C-terminal splice variants, leading to diminished morphine tolerance in mice. 17 Further exploring the molecular mechanisms of the regulation of 6TM variants expression would provide potential therapeutic targets for pain management in the future.
In conclusion, 6TM OPRM1 splice variants offer the potential of safer, effective analgesics. They illustrate the functional utility of truncated GPCR variants, which may extend beyond the opioid system. Truncated 6TM variants are not restricted to the OPRM1 gene. More than 6% of the human GPCR genes (excluding olfactory receptor genes) may potentially generate alternatively spliced 6TM variants based on genomic database analysis (unpublished observation). Our studies raise questions regarding the more general question of the pharmacological functions of truncated GPCR variants. E
